InMode's customers need to buy consumable products to use with their devices. The more consumables the company sells, the more recurring revenue it gets. Sales of its consumables are rising ...

InMode's Q1 2025 results disappointed, with revenue and EPS missing estimates, leading to a 12% stock drop and another potential guidance cut. Despite solid fundamentals and attractive valuation, ...

Medical devices company InMode (NASDAQ:INMD) has fallen out of favor with investors in the past two years for various reasons, which we'll explain below. However, now that it's down 76% from highs, ...

InMode's fundamentals remain strong despite guidance cuts, macro headwinds, and governance disputes, making current negative sentiment appear overdone. Valuation is compelling at just 9.3x forward EPS ...

InMode Ltd INMD reported Q2 sales of $136.1 million, an increase of 20% Y/Y, beating the consensus of $132 million and slightly above the preliminary numbers. Adjusted EPS reached $0.72, compared to ...

A lot of (digital) ink tends to get spilled about how much businesses grow their revenues each quarter. But sometimes, like with InMode's (NASDAQ: INMD) second-quarter earnings, the most exciting ...